{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"6.0","value":"6.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"}],"units":"Participants"}],"description":"PK accumulation will be summarized by the mean and the standard deviation.","dispersionType":"Standard Deviation","groups":[{"description":"Patients receive cabozantinib-s-malate (XL184), 40mg/m2/day orally (PO) on a continuous dosing schedule using a dosing nomogram on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"All Pharmacokinetic Patients"}],"paramType":"MEAN","populationDescription":"All patients who consented to PK or were required to consent to PK and had enough samples to estimate the PK Parameter of interest.","reportingStatus":"POSTED","timeFrame":"Cycle 1, Day 1 (20-28 hours after dose) and Cycle 1, Day 22","title":"Pharmacokinetics (PK) Parameters of Cabozantinib S-malate: Accumulation","type":"SECONDARY","unitOfMeasure":"Ratio"}